Flucytosine
- 6 April 1972
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 286 (14) , 777-778
- https://doi.org/10.1056/nejm197204062861412
Abstract
This week flucytosine (5-FC) will be released to the medical profession. It is the first new drug in approximately 15 years with activity in the systemic mycoses. The occasion prompts the following observations and caveats.The range of infections treatable with 5-FC is remarkably limited: from animal and human studies candida species and Cryptococcus neoformans. A less frequently pathogenic yeast, Torulopsis glabrata, is sensitive in vitro, and success has been claimed in three of five cases reported so far. In animal infections chemotherapeutic activity has been found against Aspergillus fumigatus, but no clinical data encountered so far . . .Keywords
This publication has 3 references indexed in Scilit:
- 5-Fluorocytosine in the Treatment of Cryptococcal and Candida MycosesAnnals of Internal Medicine, 1971
- In Vitro Studies with 5-FluorocytosineApplied Microbiology, 1969
- Treatment of Candida Sepsis and Cryptococcus Meningitis With 5-FluorocytosineJAMA, 1968